Commercial narratives have shaped the history of nicotine. For more than a century, cigarettes occupied a paradoxical place in public life. They were socially accepted, ubiquitously available and commercially profitable. However, they were eventually deemed lethal.
When electronic cigarettes entered the global marketplace in the mid-2000s, marketing geniuses presented them as a solution to a problem. Sleek, technological, and unburdened by the tar and smoke, they came with a promise of reducing harm. For millions of smokers searching for a way out, vaping was sold as an escape.
The early messaging was effective. In 2015, a widely circulated public health review in the United Kingdom estimated that e-cigarettes were “around 95 per cent less harmful than smoking.” That figure, repeated in headlines and policy discussions, legitimised vaping.
At the same time, surveys indicated that nearly half the population did not fully appreciate the difference in harm between smoking and vaping. The implication was subtle but powerful; misinformation was the real danger.
This framing aligned neatly with broader public health goals. Smoking rates, long in decline in many high-income countries, appeared to fall further as people took to vaping. Some studies suggested that smokers who used e-cigarettes achieved higher ‘quit rates’ than those relying on traditional nicotine replacement therapies.
Policymakers, wary of tobacco’s toll—estimated by the World Health Organisation to kill seven million people each year—were inclined to tolerate alternatives that might accelerate the decline of combustible smoking. Against this backdrop, vaping seemed less like a risk and more like a pragmatic compromise.
But the story is not so simple. Even as early optimism took hold, emerging research complicated the narrative. E-cigarettes, while lacking the chemicals produced by burning tobacco, were not inert. The aerosol inhaled by users contained nicotine, which is highly addictive and particularly harmful to developing brains. There were other substances, too. Vaping directly infuses heavy metals such as nickel and lead, volatile organic compounds, and flavouring agents like diacetyl, linked to serious lung disease. The absence of smoke did not mean the absence of harm; it just changed the composition of risk.
By 2019, concerns were no longer theoretical. Studies presented to major cardiovascular organisations reported that e-cigarette users exhibited elevated risk factors for heart disease, including higher levels of total and LDL cholesterol. Other research suggested that vaping could reduce blood flow to the heart, much more than traditional cigarettes. These findings challenged the assumption that “less harmful” translated into “safe,” a distinction that was often blurred in public discourse.
Meanwhile, the global expansion of vaping accelerated. Vapes, initially presented as a niche product, evolved into a multibillion-dollar industry, supported by aggressive marketing and rapid technological innovation. Devices became more efficient at delivering nicotine, flavours became varied, and branding grew sophisticated.
The language of harm reduction remained central. However, it was accompanied by imagery and design cues that resonated with younger audiences—bright colours, fruit and dessert flavours, and a sense of customisation that traditional cigarettes could not offer.
The numbers indicate remarkable growth. Since their introduction around 2006, Electronic Nicotine Delivery Systems (ENDS)—an umbrella term that includes vape pens, e-hookahs, and more advanced “mods”—have spread globally with striking speed.
In the United States and many other countries, adolescent use surged, causing alarm among public health officials. The claim that once reassured regulators—that there was no evidence e-cigarettes acted as a gateway to smoking—began to look fragile as patterns of dual use and nicotine addiction emerged among young people.
Marketing played a central role in this dangerous shift. Companies positioned vaping not only as safer but also as modern, controllable, and socially acceptable in spaces where smoking was banned. The emphasis on reduced harm, supported by selectively cited statistics, created a perception of minimal risk. However, scientific understanding of vaping’s long-term effects lagged behind its adoption, leaving a gap between what was known and what was believed.
That gap has narrowed in recent years. A growing body of research has begun to examine not just whether vaping is safer than smoking, but whether it carries risks of its own. In the absence of decades-long epidemiological data that ultimately established the link between cigarettes and lung cancer, scientists have turned to biomarkers and mechanistic studies. These approaches look for early signs of harm: changes in DNA, indicators of inflammation, and cellular alterations associated with disease.
The findings are difficult to dismiss. Analyses of blood and urine from e-cigarette users have detected the presence of carcinogenic compounds, including metals originating from device heating elements and organic chemicals produced during vaporisation.
Laboratory studies show that vaping aerosols exhibit many of the characteristics associated with known carcinogens. In both human tissues and animal models, exposure has been linked to DNA mutations and alterations in cellular processes that precede tumour development.
Particularly concerning is the evidence related to oral and lung health. Researchers have documented alterations in the tissues of the mouth and respiratory system among people who vape, including signs of oxidative stress and chronic inflammation. In some experiments, prolonged exposure to e-cigarette aerosol has resulted in the development of lung tumours, providing further grounds for concern.
Scientific consensus has shifted markedly. Between 2017 and 2019, many studies concluded that there was insufficient evidence to determine whether vaping caused cancer. By the mid-2020s, that cautious agnosticism had changed. The question is no longer whether vaping is harmless—it clearly is not—but how harmful it is, and over what time scale.
This uncertainty poses a profound challenge for public health policy. On one hand, e-cigarettes may offer a pathway away from tobacco, particularly for those who have not found success with other methods of giving up smoking. On the other hand, their widespread use introduces new risks, especially among young people and non-smokers who might never have engaged with nicotine otherwise. Balancing these considerations requires nuance that is absent from both marketing campaigns and public debates.
The scale of impact is difficult to overstate. With an estimated 1.1 billion smokers worldwide, even a partial shift toward vaping represents a massive change in patterns of nicotine consumption. If e-cigarettes were truly a “less risky” alternative, the public health benefits could be substantial. But if they carry significant long-term risks—particularly of cancer or cardiovascular disease—the consequences could unfold over decades, affecting millions of people who believed they were making a safer choice.
History offers a cautionary parallel. The link between smoking and lung cancer, first suspected in the late nineteenth century, took nearly a century to establish conclusively. During that time, uncertainty was exploited to delay regulation and sustain consumer confidence. Vaping, still in its relative infancy, exists within a similar window of incomplete knowledge. The absence of definitive long-term data does not imply safety; it reflects the simple passage of time.
Today, the speed at which both products and perceptions are evolving is a matter of concern. In less than two decades, vaping has moved from novelty to norm. Vapes are now lifestyle accessories. Its rise has been fuelled by technological innovation and a carefully crafted narrative that emphasises selective statistics and downplays uncertainty. This narrative, though effective, has also obscured the complexity of the underlying science.
As research continues, the contours of that complexity are becoming clearer. E-cigarettes are a distinct product category with their own profile of risks and unknowns. They may seem to reduce certain harms associated with smoking while introducing others that are only beginning to be understood. The stakes for public health are frightening.
The challenge is not simply to correct misconceptions but to confront the conditions that allowed them to flourish. Marketing that relies on simplified comparisons—95 per cent less harmful, fewer chemicals, cleaner delivery—can be persuasive, but it rarely captures the full picture. Public health messaging, meanwhile, must navigate the tension between encouraging smokers to quit and preventing new users from starting. In that space, clarity is often sacrificed to expediency.
There are many unresolved questions with far-reaching implications. How many cases of disease will ultimately be attributable to vaping alone? How will patterns of dual use—smoking and vaping together—shape long-term outcomes? And how can policy keep pace with an industry that continues to innovate and expand? The answers will emerge slowly, through studies that track populations over years and decades.
However, available evidence points to a simple conclusion: e-cigarettes are not the harmless alternative they were once portrayed to be, nor are they a straightforward solution to the global burden of smoking. They occupy an ambiguous space defined by partial benefits and significant risks. Millions of people have already placed themselves within that space, guided by a narrative that promised clarity where little existed.
The story of vaping offers a familiar lesson. When a product is framed as a safer choice, supported by compelling statistics and amplified through effective marketing, it can reshape behaviour on a global scale. Whether that shift reduces harm or redistributes it remains an open question—a question that will be answered not in press releases or advertising campaigns, but in the long arc of public health data yet to come.
-30-
Copyright©Madras Courier, All Rights Reserved. You may share using our article tools. Please don't cut articles from madrascourier.com and redistribute by email, post to the web, mobile phone or social media.Please send in your feed back and comments to [email protected]
